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Multicenter Study of Azole-Resistant Aspergillus fumigatus Clinical Isolates, Taiwan 1
Chi-Jung Wu, Wei-Lun Liu, Chih-Cheng Lai, Chien-Ming Chao, Wen-Chien Ko, Hsuan-Chen Wang, Ching-Tzu Dai, Ming-I Hsieh, Pui-Ching Choi, Jia-Ling Yang, Yee-Chun Chen (1) . Azole resistance in A. fumigatus might develop during patient therapy with medical azoles or through exposure to azole fungicides in the environment; environmental exposure predominantly involves TR 34 /L98H and TR 46 /Y121F/T289A mutations in cyp51A (1) .
Taiwan is an island country in eastern Asia that is geographically separated from mainland Eurasia and has a long history of azole fungicide use. To delineate the influence of clinical and environmental use of azoles on resistance, we conducted a multicenter study that investigated 375 A. fumigatus sensu stricto isolates collected during August 2011-March 2018 from 297 patients at 11 hospitals in Taiwan (Appendix Table 1 , Figure 1 , https://wwwnc.cdc.gov/EID/ article/26/4/19-0840-App1.pdf).
We confirmed the presence of azole resistance by using the Clinical Laboratory Standard Institute method (Appendix Table 1 ) (2) . Isolates resistant to >1 medical azoles (itraconazole, voriconazole, posaconazole, and isavuconazole) were defined as azole-resistant A. fumigatus and examined for resistance mechanisms, microsatellite-based phylogenetic relatedness, and growth rates following previously described methods (3, 4) .
Overall, 19 isolates from 12 patients were azole-resistant A. fumigatus. These isolates had resistance rates of 4.0%/patient and 5.1%/isolate analyses (Appendix Tables 2, 3 is consistent with the estimated global prevalence of azole resistance in Aspergillus (3%-6%) and the predominance of environmental resistance mechanisms in azole-resistant A. fumigatus (1, 5) . Phylogenetic analysis showed that TR 34 /L98H/ S297T/F495I isolates from 2 patients with pulmonary aspergillosis (isolates B44 and B51 in 2012, isolates E071, E073, and E074 in 2015) (Figure) belonged to a local microsatellite genotype widely distributed in the environment of Taiwan (3), indicating that this clone has locally evolved and adapted to the environment. The TR 34 /L98H isolates were genetically clustered with local environmental isolates or clinical isolates from China and Europe (Appendix Table 4 ). The TR 46 /Y121F/T289A isolate (S05-322) recovered in 2018, which colonized a patient without overseas travel, was genetically identical to a clone prevalent in the Netherlands and Tanzania (6), raising the concern of the intercountry transfer of resistant isolates.
All TR 34 /L98H/S297T/F495I, TR 34 /L98H, and TR 46 /Y121F/T289A isolates exhibited cross-resistance to difenoconazole and tebuconazole (both triazole fungicides) without fitness cost, demonstrated by normal growth rates (Appendix Figure 2 ). The TR 34 /L98H/S297T/F495I isolates and TR 46 /Y121F/ T289A isolates were also resistant to prochloraz (an imidazole fungicide) (Appendix Table 2 ). The prevalence of TR 34 /L98H/S297T/F495I isolates in Taiwan might be attributed to widespread use of prochloraz over the past 3 decades. Studies have suggested an association between use of imidazole fungicides and emergence of azole-resistant A. fumigatus with TR 34 / L98H/S297T/F495I mutations (7, 8) .
In Taiwan, the annual consumption of difenoconazole and tebuconazole has exceeded that of prochloraz since 2012 (Appendix Figure 3 ), further creating a favorable environment for maintenance and spread of TR 34 /L98H, TR 34 /L98H/S297T/F495I, and TR 46 /Y121F/T289A isolates. Thus, the One Health approach to implement environmental antifungal stewardship is warranted to minimize ongoing resistance selection in the fields.
Six azole-resistant A. fumigatus isolates with wildtype cyp51A were obtained from 2 patients. Four panazole-resistant urinary isolates were sequentially recovered from a patient (no. 11) with A. fumigatus renal abscesses who was receiving voriconazole for >3 months in whom an initial urine isolate was susceptible to azole; all 5 isolates were genetically identical.
Overexpression of cdr1B (a drug efflux transporter) and an S269P mutation in hmg1 (a hydroxymethylglutaryl-CoA reductase) were identified in 4 resistant isolates but not in the initial susceptible isolate (Appendix Table 5 , Figure 4 ), suggesting their roles involved in azole resistance (4, 9) . Another 2 pan-azole-resistant respiratory isolates were recovered from a patient (no. 12) who had pulmonary aspergillosis and was receiving voriconazole for 4 months. Azole-susceptible and azole-resistant isolates co-existed in this patient, which echoes the international recommendation suggesting testing multiple colonies (>5) from a single culture (1) . Cyp51A overexpression and an F262 deletion in hmg1(hmg1 F262_del ) were identified in these 2 resistant isolates. Although hmg1 F261_del was recently reported in azole-resistant A. fumigatus from a voriconazoleexposed patient (4), whether cyp51A overexpression and hmg1 F262_del act synergistically to cause resistance warrants further studies.
Finally, reduced colony sizes were observed in all 6 azole-resistant A. fumigatus isolates with wild-type cyp51A (Appendix Figure 2 ). Thus, attention should be paid to select colonies of various sizes for susceptibility testing from patients with azole exposure.
Overall, 4 patients harboring azole-resistant A. fumigatus with environmental mutations and 2 patients harboring azole-resistant A. fumigatus with wild-type cyp51A showed development of invasive aspergillosis, and all had aspergillosis-related deaths. High mortality rates for azole-resistant aspergillosis we observed (6/6, 100%) and for those from a previous report (10) emphasize the need for a proposed integrated algorithm for management and control of azole-resistant aspergillosis (Appendix Table 6 ).
In conclusion, we report a health threat that arose from clinical and environmental use of azoles; environmental use contributed at a larger and global scale. These data necessitate diagnostic stewardship in the clinic and antifungal stewardship in the environment.
